[go: up one dir, main page]

WO2009130367A1 - Procédé pour maintenir des bactéries intestinales en équilibre - Google Patents

Procédé pour maintenir des bactéries intestinales en équilibre Download PDF

Info

Publication number
WO2009130367A1
WO2009130367A1 PCT/FI2009/000053 FI2009000053W WO2009130367A1 WO 2009130367 A1 WO2009130367 A1 WO 2009130367A1 FI 2009000053 W FI2009000053 W FI 2009000053W WO 2009130367 A1 WO2009130367 A1 WO 2009130367A1
Authority
WO
WIPO (PCT)
Prior art keywords
method corresponding
microbial
bacteria
patent specifications
action
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FI2009/000053
Other languages
English (en)
Inventor
Eino Elias Hakalehto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP09735666A priority Critical patent/EP2280612A4/fr
Publication of WO2009130367A1 publication Critical patent/WO2009130367A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics

Definitions

  • the human digestive tract and intestines similarly to those of all warm-blooded animals, consist of a number of different environments in terms of microbial action. Not all microbes can survive in all sections of the digestive tract. In addition, these parts of the system are a setting for competition between microbes, but also interaction associated with possibilities of survival, finding nutrition and propagation. In order to be able to function in the digestive tract or the various intestinal segments of which it is composed, the microbes must have properties that enable them to act in this environment. These properties may include the utilization of certain nutrients, ability to adhere to mucous membranes, tolerance to or production of antibiotics, or adaptation to certain types of environmental conditions, such as a low pH or partial pressure of oxygen.
  • the body's defence system is on guard to fight microbial overgrowth in the intestine, and even in the various segments of the small intestine. It is commonly thought that unlike to what is found in the large intestine, rich microbiota or biofilms capable of using components of human food do not occur on the surfaces of the small intestine.
  • the large intestine acts as a type of sewer in the body, through which significant amounts of wastes are eliminated. Microbial growth in the small intestine is regulated by such as the secretion and occurrence of bile acids. Consequently, microbes with a high tolerance to bile acid usually flourish in this area.
  • microbial balance in the intestine plays an important role in our state of health. This usually refers to the microbiota of the large intestine. Attempts are being made to improve the composition of the so-called normal flora in the large intestine by microbes contained in food or food supplements, mainly bacteria which in studies have been found to, or which are expected to, have a favourable influence on microbial balance, composition of the normal flora and our health and general condition. Studies strive to prove various favourable effects demonstrated as lower incidence rates of many infectious diseases and other illnesses.
  • the changes caused by microbial action in the microbiota of the digestive tract can be measured based on the occurrence of bacterial metabolites or waste products. These substances can be measured in the body in such as the blood stream, expired air, intestinal gases, on the skin or elsewhere with a sensor placed in this area or by analysing a sample collected in this area. Changes in action or composition of microbiota can also be gauged by analysing the contents of antibodies occurring in the blood stream, mucous membranes, faecal samples, saliva or elsewhere in the body. Description of the Invention
  • a vector can be a powder, solution, tablet, capsule or corresponding.
  • such techniques can further contain growth factors or nutrients needed by the microbes, or even antibiotics to prevent the action or to reduce the vitality of competing microbes.
  • the usual aim is to work on microbial action in the large intestine.
  • the microbial strain to be transferred needs not only a vector but often also a means of getting the strain to colonise the right area and to maintain its functional ability there for as long as possible.
  • methods can be developed to improve the adherence of desirable microbes to the various segments of the digestive tract.
  • the composition of the human intestinal flora is mainly determined during a person's very first years of life. This is why we can assume that effectively achieving consequences that make an essential difference in an individual's state of health will, besides sufficiently long-term and continuous use, require:
  • facultatively anaerobic bacteria occur, which are able to act either aerobically when oxygen is present, or anaerobically without oxygen.
  • these bacteria have particular biochemical properties through which they can perform reactions necessary for their vital functions and growth.
  • anaerobic metabolism can be as efficient as its aerobic counterpart, at least momentarily (Hakalehto et al. 2007).
  • the end products of anaerobic metabolism are known as fermentation products.
  • Typical metabolic routes used by facultative anaerobic microbes include mixed acid fermentation, lactic acid fermentation, propionic acid fermentation and butylene glycol fermentation.
  • the last- mentioned fermentation reaction differs from the others in that its products are mainly neutral, such as alcohols.
  • What plays a crucial role for the digestive tract and the whole body is the type of facultative anaerobic bacteria that are dominant, or active, in the intestinal canal at any one time. This is particularly significant in the small intestine, where a considerable part of the nutrients used by the body are absorbed.
  • Another background factor to weight gain may be the fact that certain alcohols, such as ethylic alcohol, which are high-energy nutrients, are rapidly absorbed by the body in the intestine. In proportion, butylene glycol fermentation produces more ethanol than mixed acid fermentation.
  • ethylic alcohol which are high-energy nutrients
  • butylene glycol fermentation produces more ethanol than mixed acid fermentation.
  • the composition of microbial flora plays an indirect role in the development of such illnesses as diabetes, heart diseases or hypertension, or in the prevention of their causes, such as the progress of obesity.
  • Forming, finding and maintaining a balance between acid fermentation processes and neutral alcohol fermentation processes of facultative anaerobic bacteria is a vital principle for the wellbeing of the entire digestive tract. This can be efficiently influenced by adding bacteria performing either acid fermentation or butylene glycol fermentation, or both, to the food or food supplements in the right proportions and at the right time. This balance can also be indirectly influenced by changing the internal status of the intestinal canal through food or nutritional or pharmaceutical components added to it.
  • antibiotics which can be used to control the development of microbial flora.
  • the intake of alcohol favours microbes highly tolerant to alcohol, and on the other hand, ingesting various acids, such as acetic acid, changes the intestinal balance towards a more acidic direction.
  • composition of microbiota of the intestinal canal in particular to find out what types of facultative anaerobic microbes are working at a particular time, this can be achieved e.g. by measuring the contents and/or proportions of metabolites, organic acids and alcohols produced by precisely those microbes in the body, for example in the blood stream, expired air, intestinal gases or various tissues, or on the skin.
  • the composition of saliva, perspiration or other secretions can be analysed for this purpose.
  • the contents of antibodies in various parts of the body can be determined, for example in the blood stream, mucous membranes, saliva, various tissues or in faecal samples.
  • the acidity levels of various parts of the system can also be monitored by measurements. All measurement data described here can be used as a basis for the use of microbial strains or supplements affecting their action as described in this invention.
  • the aim is at natural regulation of pH values in the intestine, and in the small intestine in particular, that promotes good health, thus improving and maintaining personal health and wellbeing.
  • Typical members of facultative microbial flora are Escherichia coli and most other members of the family Enterobacteriaceae performing mixed acid fermentation, lactobacilli and streptococci performing lactic acid fermentation, and bacterial genera performing butylene glycol fermentation, Enterobacter, Klebsiella and Serratia.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un procédé permettant une nouvelle façon de réguler les conditions de pH et l'équilibre microbien de l'intestin grêle et du canal intestinal entier en ce qui concerne des bactéries anaérobies facultatives, permettant à cette régulation d'être basée sur l'utilisation de données de mesure obtenues à partir du système. Celui-ci peut être particulièrement significatif dans la prévention de diverses maladies et de l'obésité, ainsi que dans le maintien d'un bon état de santé.
PCT/FI2009/000053 2008-04-25 2009-04-24 Procédé pour maintenir des bactéries intestinales en équilibre Ceased WO2009130367A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09735666A EP2280612A4 (fr) 2008-04-25 2009-04-24 Procédé pour maintenir des bactéries intestinales en équilibre

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20080321 2008-04-25
FI20080321A FI20080321A0 (fi) 2008-04-25 2008-04-25 Menetelmä suoliston bakteeritasapainon ylläpitämiseksi

Publications (1)

Publication Number Publication Date
WO2009130367A1 true WO2009130367A1 (fr) 2009-10-29

Family

ID=39385889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2009/000053 Ceased WO2009130367A1 (fr) 2008-04-25 2009-04-24 Procédé pour maintenir des bactéries intestinales en équilibre

Country Status (3)

Country Link
EP (1) EP2280612A4 (fr)
FI (1) FI20080321A0 (fr)
WO (1) WO2009130367A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035014A2 (fr) * 1997-02-11 1998-08-13 Enterprise Ireland Trading As Bioresearch Ireland Souches probiotiques provenant de lactobacillus salivarius et agents antimicrobiens obtenus a partir de celles-ci
WO1999059413A1 (fr) * 1998-05-15 1999-11-25 Shanghai Sine Pharmaceutical Corp., Ltd. Composition microbienne benefique, nouvelles matieres de protection pour microbes et procedes de preparation et d'utilisation d'une telle composition
WO2001011077A2 (fr) * 1999-08-11 2001-02-15 Cedars-Sinai Medical Center Methodes de diagnostic ou de traitement du syndrome du colon irritable et d'autres troubles lies a une proliferation bacterienne dans l'intestin grele
WO2002060276A1 (fr) * 2001-01-25 2002-08-08 Valio Ltd Combinaison de probiotiques
WO2004022727A1 (fr) * 2002-09-06 2004-03-18 Vri Biomedical Ltd Bacterie probiotique : lactobacillus fermentum
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2007071815A1 (fr) * 2005-12-22 2007-06-28 Cyflo Oy Procédé de surveillance et de promotion de l'alimentation et du bien-être d'un animal et/ou d'un être humain ainsi que de la productivité d'animaux
EP2030623A1 (fr) * 2007-08-17 2009-03-04 Nestec S.A. Prévention et/ou traitement de troubles métaboliques par la modulation de la quantité d'entérobactéries

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165661A1 (en) * 2003-06-13 2006-07-27 N>V> Nutricia Pediocin-producing pediococci
EP2020869B1 (fr) * 2006-05-01 2013-10-16 Universiteit Gent Combinaison de poly-3-hydroxybutyrate et depolymerase en tant que composants d'aliments pour animaux ou d'additifs aux aliments pour animaux
CA2690058A1 (fr) * 2006-06-09 2007-12-13 9205-5961 Quebec Inc. Compositions probiotiques derivees de produits laitiers et leurs utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035014A2 (fr) * 1997-02-11 1998-08-13 Enterprise Ireland Trading As Bioresearch Ireland Souches probiotiques provenant de lactobacillus salivarius et agents antimicrobiens obtenus a partir de celles-ci
WO1999059413A1 (fr) * 1998-05-15 1999-11-25 Shanghai Sine Pharmaceutical Corp., Ltd. Composition microbienne benefique, nouvelles matieres de protection pour microbes et procedes de preparation et d'utilisation d'une telle composition
WO2001011077A2 (fr) * 1999-08-11 2001-02-15 Cedars-Sinai Medical Center Methodes de diagnostic ou de traitement du syndrome du colon irritable et d'autres troubles lies a une proliferation bacterienne dans l'intestin grele
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2002060276A1 (fr) * 2001-01-25 2002-08-08 Valio Ltd Combinaison de probiotiques
WO2004022727A1 (fr) * 2002-09-06 2004-03-18 Vri Biomedical Ltd Bacterie probiotique : lactobacillus fermentum
WO2007071815A1 (fr) * 2005-12-22 2007-06-28 Cyflo Oy Procédé de surveillance et de promotion de l'alimentation et du bien-être d'un animal et/ou d'un être humain ainsi que de la productivité d'animaux
EP2030623A1 (fr) * 2007-08-17 2009-03-04 Nestec S.A. Prévention et/ou traitement de troubles métaboliques par la modulation de la quantité d'entérobactéries

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAKALEHTO, E. ET AL.: "Dualistic acidic and neutral glucose fermentation balance in small intestine: Simulation in vitro", PATHOPHYSIOLOGY, vol. 15, no. 4, 2008, pages 211 - 220, XP025712671 *
QUIGLEY E.M.M. ET AL.: "Small Intestinal Bacterial Overgrowth: Roles of Antibiotics, Prebiotics, and Probiotics", GASTROENTEROLOGY, vol. 130, no. 2, 2006, pages S78 - S90, XP005284758 *
See also references of EP2280612A4 *

Also Published As

Publication number Publication date
FI20080321A0 (fi) 2008-04-25
EP2280612A4 (fr) 2011-10-05
EP2280612A1 (fr) 2011-02-09

Similar Documents

Publication Publication Date Title
Yu et al. Dietary supplemented antimicrobial peptide microcin J25 improves the growth performance, apparent total tract digestibility, fecal microbiota, and intestinal barrier function of weaned pigs
Su et al. Lotus seed oligosaccharides at various dosages with prebiotic activity regulate gut microbiota and relieve constipation in mice
Montelius et al. Feeding spinach thylakoids to rats modulates the gut microbiota, decreases food intake and affects the insulin response
Feng et al. The effects of dietary Lactococcus spp. on growth performance, glucose absorption and metabolism of common carp, Cyprinus carpio L.
CN110893193B (zh) 乳双歧杆菌bl-99的新应用
Kim et al. Lactobacillus brevis OK56 ameliorates high-fat diet-induced obesity in mice by inhibiting NF-κB activation and gut microbial LPS production
JP5674741B2 (ja) 消化器疾患に関連する症状の緩和に使用されるプロバイオティクス
Yang et al. Galacto-oligosaccharides modulate gut microbiota dysbiosis and intestinal permeability in rats with alcohol withdrawal syndrome
CN115287207B (zh) 乳双歧杆菌ty-s01在制备预防或缓解便秘的药品中的应用
JP7262391B2 (ja) フソバクテリウム属細菌および／またはステレラ属細菌の菌数抑制剤
JP6475162B2 (ja) プレバイオティックチラコイド組成物
Li et al. Synbiotic supplementation with xylooligosaccharide derived probiotic Lactobacillus gasseri and prebiotic mixture exerts antidiabetic effects via collaborative action
TWI719549B (zh) 促進嗜黏蛋白艾克曼菌生長之益生質組合物
WO2022190072A1 (fr) Formulations de fer (iii) pour le traitement d'une inflammation gastro-intestinale
Abdulazeez et al. Probiotic (protexin) modulates glucose level in sucrose-induced hyperglycaemia in Harwich strain Drosophila melanogaster
US11850270B2 (en) Probiotics and methods of use
Fox et al. Effects of mucin and its carbohydrate constituents on Escherichia coli O157 growth in batch culture fermentations with ruminal or fecal microbial inoculum
WO2009130367A1 (fr) Procédé pour maintenir des bactéries intestinales en équilibre
Chen et al. The human microbiota and its therapeutic options
WO2020176624A1 (fr) Probiotiques et compositions probiotiques ayant un métabolisme des glucides modifié
CN117100772A (zh) 植物乳杆菌shy21-2在增加耐力缓解疲劳中的应用
CN118726209B (zh) 一种用于改善宠物犬毛光泽度及体重管理的益生菌及其应用
ES2367518T3 (es) Lactobacilli probióticos felinos.
Gupta et al. Significance of the normal microflora of the body
KR20250106029A (ko) 크리스텐시넬라 미누타를 포함하는 지방간 질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09735666

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009735666

Country of ref document: EP